Abeprazan hydrochloride

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Abeprazan (DWP14012) hydrochloride 是一种钾竞争性酸 (potassium-competitive acid) 阻滞剂。Abeprazan hydrochloride 通过可逆的钾竞争性离子结合抑制 H+，K+- ATPase，而无需酸激活。Abeprazan hydrochloride 是一种潜在的质子泵抑制剂，用于研究与酸相关的疾病。

Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases.

The mechanism of action of Abeprazan hydrochloride is reversibly binding to H+, K+‐ATPase, and, unlike that of PPIs, does not require acidic environment for drug activation.

Abeprazan hydrochloride (DWP14012 hydrochloride) inhibits acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion is equal to or greater than that of vonoprazan, a previously approved P-CAB, in various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models.

——

Membrane Transporter/Ion Channel

Proton Pump

Proton pump

——

——

1902954-87-3

446.87

C19H18ClF3N2O3S

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 25 mg/mL (55.94 mM; 超声助溶 )

Cl.CNCc1cn(c(c1OC)-c1ccc(F)cc1F)S(=O)(=O)c1cccc(F)c1

——

(-20℃)

With Ice Pack

≥ 2 years